Clinical Trials Browser

Phase 2 × Interleukin-12 Subunit p35 × Dermatologic × Clear all

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00003210 2015-04-15

Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease

DermatologicLymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00003339 2014-05-22

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Phase 2 Completed

48 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT00031733 2014-05-22

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Phase 2 Completed

60 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT00026143 2013-06-05

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Phase 2 Completed

60 enrolled

Dermatologic

Melanoma

Clinical Trials

NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)

Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma